Skip to main content

BGI Europe, NIM Genetics Reach Agreement on NIPT for Spain

NEW YORK (GenomeWeb) — BGI Europe has inked an exclusive technology transfer deal with Spain's NIM Genetics for BGI Europe's non-invasive prenatal testing technology.

The deal allows NIM to begin offering BGI Europe's NIPT in Spain. The test, called TrisoNIM Advance and marketed as Nifty in other parts of Europe, detects the risk of genetic conditions such as Down syndrome from as early as 10 weeks into the pregnancy.

The deal follows other deals forged by BGI Europe, the European branch of BGI, to make Nifty available in Italy and Poland

 

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.